A biotech startup let an agent choose a gene therapy and successfully inject the treatment, offering a startling glimpse of the future of research labs.

In breathless press releases and posts, the company has touted its models’ ability to deliver scientific breakthroughs. But its IPO filing taps the brakes on just how fast its AI will lead to big discoveries.

This week on “Uncanny Valley,” we go behind the scenes of our Nathan Fielder cover story, unpack tech billionaires’ generous promises, and discuss the suspicious letters sent to US election offices.

It’s the latest in a growing wave of bets that AI companies are making on brain data.